Glaukos stock reports 49.60 percent Q2 revenue growth

Published on 10/01/2026 at 07:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Glaukos stock faces a USD 168.00 Argus target after the September 23, 2026 reduction. Q2 revenue reached USD 185.61 million, up 49.60 percent year over year.

GKOS, US3773221029, Illustration mit AI erstellt.

Glaukos stock is anchored by Q2 2026 revenue of USD 185.61 million, a 49.60 percent year-over-year increase, while the prior close at Lang & Schwarz was EUR 144.50 on September 29, 2026. The company remains in a high-growth but loss-making phase as analysts reassess valuation after the latest results.

Revenue beats expectations

MarketBeat reported on September 29, 2026, that Glaukos generated USD 185.61 million in Q2 revenue against a USD 150.93 million consensus estimate. The same report put adjusted EPS at a USD 0.14 loss versus an expected USD 0.21 loss, an improvement of USD 0.07 per share against consensus.

The comparison with the prior-year quarter is the key operating signal: revenue rose 49.60 percent, while the adjusted loss narrowed from USD 0.24 per share in the same quarter of 2025. Glaukos therefore delivered stronger top-line momentum even as profitability remained negative.

Analyst targets diverge

Argus lowered its Glaukos target to USD 168.00 in a report dated September 23, 2026, according to Yahoo Finance. That target contrasts with the USD 195.00 objective from Piper Sandler, raised from USD 165.00 in a July 30, 2026 report cited by MarketBeat.

The gap between USD 168.00 and USD 195.00 shows how much the valuation depends on execution in Glaukos products for glaucoma and corneal disorders. MarketBeat also reported that the stock moved below its USD 171.71 50-day moving average on September 29, 2026, adding a technical counterweight to the revenue growth story.

Prior close and company profile

The prior close at Lang & Schwarz was EUR 144.50 on September 29, 2026. Glaukos launched its latest disease-awareness campaign with Stephen Curry on September 23, 2026, according to MarketScreener. The initiative targets earlier recognition of keratoconus and supports the company strategy of expanding beyond glaucoma therapies.